NCT04850664 (CBOT-OUD) is a Phase 2 clinical trial of CBOT + TAU in Opioid Use Disorder, Moderate, sponsored by Evon Medics LLC.

Who is sponsoring NCT04850664?

NCT04850664 is sponsored by Evon Medics LLC.

What drugs are being tested in NCT04850664?

Interventions in NCT04850664: CBOT + TAU, Sham + TAU.

What condition does NCT04850664 study?

NCT04850664 studies Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving, Negative Affectivity.

Is NCT04850664 still recruiting?

NCT04850664 is currently status unknown. Last updated 6 August 2021.

Last reviewed 2021-08-06 · How we verify

NCT04850664: CBOT-OUD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder

Status unknown Phase 2 Last updated 6 August 2021

What this trial tests

Phase 2 trial testing CBOT + TAU in Opioid Use Disorder, Moderate in 190 participants. Status unknown.

Timeline

26 March 2021

Primary endpoint
30 November 2022

31 December 2022

Quick facts

Lead sponsor	Evon Medics LLC
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	190
Start date	26 March 2021
Primary completion	30 November 2022
Estimated completion	31 December 2022
Sites	4 locations across United States

Drugs / interventions tested

CBOT + TAU — full drug profile →
Sham + TAU — full drug profile →

Conditions studied

Opioid Use Disorder, Moderate — all drugs for Opioid Use Disorder, Moderate →
Opioid Use Disorder, Severe — all drugs for Opioid Use Disorder, Severe →
Withdrawal Symptoms — all drugs for Withdrawal Symptoms →
Craving — all drugs for Craving →

Sponsor

Evon Medics LLC — full company profile →

Who can join

Adults 18 to 70, any sex, with Opioid Use Disorder, Moderate or Opioid Use Disorder, Severe. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Opioid Use Disorders (OUD) cause significant burden to individuals, families, and the society. Our product - Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) - offers a cost-saving, home-based, user-friendly brain stimulation system that increased 6-month treatment retention of OUDs in a pilot study; and also, acutely reduced opioid withdrawal severity and negative affect during induction into opioid maintenance therapy. This study will establish its effectiveness in a broad category of OUD subjects at different stages of OUD care continuum.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Trends of Decentralized Clinical Trials Using Digital Technology for Decentralization
Sato T, Mizumoto S, Ota M, Shikano M. · · 2022 · DOI 10.2139/ssrn.4243284

Verify or expand the search:

Other recruiting trials for Opioid Use Disorder, Moderate

Currently open trials in the same condition.

NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting
NCT04921787 — EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy · NA · active not recruiting

Other Evon Medics LLC trials

Trials by the same sponsor.

NCT06671132 — Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBO · Phase 2 · recruiting
NCT06434818 — Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders · Phase 2 · recruiting
NCT06218407 — Development and Evaluation of Computerized Chemosensory Based Orbitofrontal Networks Training for Treatment of Pain · Phase 1 · completed
NCT05122598 — Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04850664 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Evon Medics LLC
Last refreshed: 6 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04850664.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing